AUTHORS
Brenda Sofia Castillo, MD, Jenna Voutsinas, MPH2, Qian Wu, PhD3, David Garcia I, MD4, Jesse Fajnzylber, MD, MS5, McKayla Deisz6, Sameer A. Parikh, MBBS7, Paul J. Hampel, MD8, Lindsey Elizabeth Roeker, MD9, Vincenzo Pizzuti, MD, MS10, Manali Kamdar, MD11, Paolo Lopedote, MD12, Alexey V. Danilov, MD, PhD13, Benjamin J. Lee, PharmD14, Catherine C. Coombs, MD15, Nicolas Duque, MD16, Georgios N. Pongas, M.D.17, Daniel DeAvila Jr, M.S.18, Javier Pinilla-Ibarz, MD PhD19, Ryan Jacobs, MD20, Ajay Gopal, MD21, Chaitra Ujjani, MD22, Stephen Douglas Smith, MD23, Paul S Martin, MD24, Brian G Till, MD25, Ryan C Lynch, MD26, Mengyang Di, MD, PhD27, Jennifer J. Huang, MD, PhD28, Alexis Green29, Danielle Brander, MD30, Adan Askari31, Eli P. Darnell32, Seema Ali Bhat, MD33, Alan Skarbnik, MD34, Joanna M Rhodes, MD, MSCE35, Sarah S. Makhani, MD36, Adam Kittai, MD37, Kylee L. Martens, MD38, Joseph Shatzel, MD39, Stephen E. Spurgeon, MD40, Mazyar Shadman, MD, MPH41
AFFILIATIONS
1 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
2 Fred Hutch Cancer Center, Seattle, United States
3 Fred Hutch Cancer Center, Seattle, United States
4 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 University of Colorado Cancer Center, Denver, Colorado, United States
11 University of Colorado Cancer Center, Denver, Colorado, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 University of California Irvine Health, Irvine, California, United States
15 University of California Irvine Health, Irvine, California, United States
16 University of Miami, Miami, Florida, United States
17 Moffitt Cancer Center, H Lee Moffitt Cancer Center and Research Institute,, Tampa, Florida, United States
18 Moffitt Cancer Center, H Lee Moffitt Cancer Center and Research Institute,, Tampa, Florida, United States
19 Moffitt Cancer Center, H Lee Moffitt Cancer Center and Research Institute,, Tampa, Florida, United States
20 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
21 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
22 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
23 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
24 University of Washington, Seattle, Washington, United States
25 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
26 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
27 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
28 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
29 Duke University School of Medicine, Durham, North Carolina, United States
30 Duke University School of Medicine, Durham, North Carolina, United States
31 Pritzker School of Medicine, University of Chicago, Chicago, Illinois, United States
32 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
33 James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, Ohio, United States
34 University of North Carolina School of Medicine Novant Health Cancer Institute, Charlotte, North Carolina, United States
35 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
36 New York University, Perlmutter Cancer Center, New York, New York, United States
37 New York University, Perlmutter Cancer Center, New York, New York, United States
38 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States
39 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States
40 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States
41 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
ABSTRACT
Introduction: Bruton tyrosine kinase inhibitors (BTKis)-acalabrutinib (acala), zanubrutinib (zanu), and pirtobrutinib (pirto)- are treatments(tx) for CLL/SLL. Bleeding is a complication of BTKis. It is common for patients (pts) with CLL/SLL to be on anticoagulation (AC) due to venous thromboembolism (VTE) or atrial fibrillation (AF). To our knowledge the risk of major and minor bleeding events (BEs) across BTKis has not been stratified by AC agent. We report the rates of major and minor BEs in pts with CLL/SLL treated with concurrent BTKi+DOAC.
Methods: We conducted a multicenter retrospective study to evaluate the rates of major and minor BEs in pts with CLL/SLL treated with concurrent BTKi+DOACs at 15 sites in the US from December 2019-December 2025. Major and minor BEs were captured utilizing the International Society on Thrombosis and Haemostasis guidelines. A major BE was fatal bleeding, and/or bleeding in a critical area (eg, intracranial, pericardial, and others), and/or bleeding with Hb drop ≥ 2 g/dL, and/or bleeding requiring transfusion of ≥ 2 units of whole blood or pRBCs. A minor BE is bleeding not meeting criteria for major BE. BTKis examined were acala, zanu, and pirto. Ibrutinib was excluded. Anticoagulants were: apixaban, rivaroxaban, dabigatran, heparin, low molecular weight heparin and warfarin. Demographic and clinical characteristics were obtained: comorbidities, BEs preceding BTKi+DOAC tx, antiplatelet drugs, baseline anemia and chronic thrombocytopenia (TCP), and subsequent BEs. Chronic TCP was ≥2 plt values <100 ×10⁹/L within 6 months prior to initiation of BTKi+DOAC. BEs were attributed to the specific BTKi+DOAC combination used during the BE.
Results: The study includes 146 pts; the median age during concurrent BTKi+DOAC tx was 74 (range 67-81), and 109 (75%) were male. Ninety-six (66%) had history of hypertension (HTN), 10 (7.0%) had uncontrolled HTN, 68 (47%) CKD, 36 (25%) chronic TCP, 16 (11%) prior intracranial hemorrhage (ICH), and 11 (7.5%) prior GI bleed. The median Hb prior to BTKi+DOAC was 12.2 g/dL (IQR, 10.8-13.8). Antiplatelets used: aspirin, 9 (69.1%), aspirin and clopidogrel, 2 (15.4%), ticagrelor, 1 (7.7%), and clopidogrel, 1 (7.7%). Six pts had ≥ 1 BTKi switch during overlap and 5 pts had ≥ 1 DOAC switch. Seventy-nine (54%) pts were on acala as their sole BTKi, 49 (33.7%) on zanu and 12 (8.2%) on pirto. Apixaban was the most used AC agent 137 (93%). Pts had ≥ 1 indication for AC: AF (56%), VTE (45%), prosthetic valves (0.5%), and others (1.0%). The most used BTKi+DOAC was acala+apixaban in 55(38%) pts. Thirteen pts (8.9%) got an antiplatelet agent with BTKi+DOAC (triple therapy).
The median follow-up for BTKi+DOAC use was 472 days (IQR, 154-896). 2-year bleed free probability was 88%, 95% CI 81-95%. Fifteen (10%) pts had ≥1 major BEs for a total of 19 major BEs. Bleeding sites were ICH in 7 (37%) pts, GI in 3 (16%), mucocutaneous in 3 (16%), procedure related in 2 (11%), pulmonary in 2 (11%), genitourinary in 1 (5.3%), and cardiac tamponade in 1 (5.3%). Of the 15 pts with a major BE, 1 was on acala+apixaban+aspirin, and had an ICH. Two pts had major BE-related death due to ICH on day 26 and cardiac tamponade on day 437 of BTKi+DOAC. Both pts were on zanu+apixaban only. Sixty-six (45.2%) pts had ≥ 1 minor BEs. Four pts (2.7%) had minor BEs while on triple therapy. The rate of major BEs was 20% (n=1) of pts on dabigatran, 10% (n=11) on apixaban, and 11% (n=3) on rivaroxaban. The rate of major BEs was 12% (n=10) of pts on acala, 12% (n=2) on pirto, and 6% (n=3) on zanu. On univariable Cox regression, BTKi and AC types were not significantly associated with major BEs. Compared to acala (ref) the HR were 1.58 (95%CI, 0.43-5.84; p=0.5) for pirto, and 0.77(95% CI, 0.21-2.93; p=0.7) for zanu. Compared to apixaban (ref), HR was 3.04(95% CI, 0.38-24.2; p=0.3) for dabigatran and 0.63(95%CI, 0.14-2.82; p=0.5) for rivaroxaban.
Conclusion: In this large multicenter retrospective study of pts treated with BTKi+DOAC, 10% of pts had major BE during a median exposure of 472 days. Although many pts had ≥ 1 risk factors for bleeding, the 2-year probability of remaining free from major BEs was 88%. Differences in BEs’ rates among individual BTKis and DOACs should be interpreted with caution given the small sample size and potential confounding. Prospective studies are needed to better define bleeding risk, identify predictors of bleeding risk, and optimize AC in pts with CLL/SLL receiving BTKis.
DISCLOSURES
Brenda Sofia Castillo, MD: No relevant conflicts of interest to declare.